Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations i...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2016-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/ncomms13665 |
| _version_ | 1819040300060901376 |
|---|---|
| author | Beth O. Van Emburgh Sabrina Arena Giulia Siravegna Luca Lazzari Giovanni Crisafulli Giorgio Corti Benedetta Mussolin Federica Baldi Michela Buscarino Alice Bartolini Emanuele Valtorta Joana Vidal Beatriz Bellosillo Giovanni Germano Filippo Pietrantonio Agostino Ponzetti Joan Albanell Salvatore Siena Andrea Sartore-Bianchi Federica Di Nicolantonio Clara Montagut Alberto Bardelli |
| author_facet | Beth O. Van Emburgh Sabrina Arena Giulia Siravegna Luca Lazzari Giovanni Crisafulli Giorgio Corti Benedetta Mussolin Federica Baldi Michela Buscarino Alice Bartolini Emanuele Valtorta Joana Vidal Beatriz Bellosillo Giovanni Germano Filippo Pietrantonio Agostino Ponzetti Joan Albanell Salvatore Siena Andrea Sartore-Bianchi Federica Di Nicolantonio Clara Montagut Alberto Bardelli |
| author_sort | Beth O. Van Emburgh |
| collection | DOAJ |
| description | Some colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations in the extracellular domain of EGFR. |
| first_indexed | 2024-12-21T09:06:54Z |
| format | Article |
| id | doaj.art-24cf071741ce4d09aa89b3a6aab76cd5 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-21T09:06:54Z |
| publishDate | 2016-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-24cf071741ce4d09aa89b3a6aab76cd52022-12-21T19:09:19ZengNature PortfolioNature Communications2041-17232016-12-01711910.1038/ncomms13665Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancerBeth O. Van Emburgh0Sabrina Arena1Giulia Siravegna2Luca Lazzari3Giovanni Crisafulli4Giorgio Corti5Benedetta Mussolin6Federica Baldi7Michela Buscarino8Alice Bartolini9Emanuele Valtorta10Joana Vidal11Beatriz Bellosillo12Giovanni Germano13Filippo Pietrantonio14Agostino Ponzetti15Joan Albanell16Salvatore Siena17Andrea Sartore-Bianchi18Federica Di Nicolantonio19Clara Montagut20Alberto Bardelli21Candiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSCandiolo Cancer Institute—FPO, IRCCSNiguarda Cancer Center, Grande Ospedale Metropolitano NiguardaMedical Oncology Department, Hospital del MarCancer Research Program, FIMIM (Hospital del Mar Medical Research Institute), Hospital del MarCandiolo Cancer Institute—FPO, IRCCSMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei TumoriMedical Oncology Division 1, Colorectal Cancer Unit, San Giovanni Battista HospitalMedical Oncology Department, Hospital del MarNiguarda Cancer Center, Grande Ospedale Metropolitano NiguardaNiguarda Cancer Center, Grande Ospedale Metropolitano NiguardaCandiolo Cancer Institute—FPO, IRCCSMedical Oncology Department, Hospital del MarCandiolo Cancer Institute—FPO, IRCCSSome colorectal cancer patients respond well to treatment with anti-EGFR antibodies, however response is almost invariably followed by acquired resistance. Here, the authors show that patients with shorter responses acquireRAS mutations, while those relapsing later preferentially develop mutations in the extracellular domain of EGFR.https://doi.org/10.1038/ncomms13665 |
| spellingShingle | Beth O. Van Emburgh Sabrina Arena Giulia Siravegna Luca Lazzari Giovanni Crisafulli Giorgio Corti Benedetta Mussolin Federica Baldi Michela Buscarino Alice Bartolini Emanuele Valtorta Joana Vidal Beatriz Bellosillo Giovanni Germano Filippo Pietrantonio Agostino Ponzetti Joan Albanell Salvatore Siena Andrea Sartore-Bianchi Federica Di Nicolantonio Clara Montagut Alberto Bardelli Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer Nature Communications |
| title | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer |
| title_full | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer |
| title_fullStr | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer |
| title_full_unstemmed | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer |
| title_short | Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer |
| title_sort | acquired ras or egfr mutations and duration of response to egfr blockade in colorectal cancer |
| url | https://doi.org/10.1038/ncomms13665 |
| work_keys_str_mv | AT bethovanemburgh acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT sabrinaarena acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giuliasiravegna acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT lucalazzari acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giovannicrisafulli acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giorgiocorti acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT benedettamussolin acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT federicabaldi acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT michelabuscarino acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT alicebartolini acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT emanuelevaltorta acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT joanavidal acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT beatrizbellosillo acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT giovannigermano acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT filippopietrantonio acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT agostinoponzetti acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT joanalbanell acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT salvatoresiena acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT andreasartorebianchi acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT federicadinicolantonio acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT claramontagut acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer AT albertobardelli acquiredrasoregfrmutationsanddurationofresponsetoegfrblockadeincolorectalcancer |